Fundraising Fox
Xap Therapeutics
Cambridge, GB · 1 known investors
Find your way into Xap Therapeutics
Sign up to see every warm intro you have to Xap Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Xap Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Xap Therapeutics uses genome editing and synthetic biology to engineer a programmable cell-based delivery platform that carries therapeutic payloads such as cytokines, antibodies, and nucleic acids, releasing them upon target recognition. It is developing multi-modal therapies for complex diseases including cancer and autoimmunity.
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- XAP THERAPEUTICS LIMITED
- Company number
- 10613866
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 10 Feb 2017
- Registered office
- Babraham Research Campus, Maia Building (B270), Cambridge, CB22 3AT
- Nature of business (SIC)
- 64303 — Activities of venture and development capital companies
- Previous names
- ROCKEND LIMITED (2017–2021)
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 9 Feb 2026 · next due 23 Feb 2027
Current officers · 5
- Josephine Angela Stevens — secretary, appointed 19 Jul 2022
- Shaun Patrick Foy — director, appointed 10 Feb 2017
- Simeon John George — director, appointed 5 Sept 2017
- Mahesh Kudari — director, appointed 6 Aug 2025
- Rodger Novak — director, appointed 27 Apr 2020
Source: Companies House public register · retrieved 20 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Xap Therapeutics do?
- Xap Therapeutics uses genome editing and synthetic biology to engineer a programmable cell-based delivery platform that carries therapeutic payloads such as cytokines, antibodies, and nucleic acids, releasing them upon target recognition. It is developing multi-modal therapies for complex diseases including cancer and autoimmunity.
- Who are Xap Therapeutics's investors?
- Xap Therapeutics's investors include SR One Capital Management.
- Where is Xap Therapeutics headquartered?
- Xap Therapeutics is headquartered in Cambridge, GB.